Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $45.54.
TNGX has been the subject of several analyst reports. William Blair assumed coverage on Tango Therapeutics in a report on Friday, October 16th. They set an “outperform” rating for the company. JPMorgan Chase & Co. lifted their target price on shares of Tango Therapeutics from $46.00 to $47.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 10th. Stifel Nicolaus set a $55.00 target price on shares of Tango Therapeutics in a research note on Friday, October 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tango Therapeutics in a report on Wednesday, November 4th. Finally, Wall Street Zen cut shares of Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th.
View Our Latest Analysis on Tango Therapeutics
Tango Therapeutics Stock Performance
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.04). As a group, analysts forecast that Tango Therapeutics will post -1.46 EPS for the current year.
Insider Transactions at Tango Therapeutics
In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $24.47, for a total value of $660,690.00. Following the transaction, the insider owned 115,743 shares in the company, valued at approximately $2,832,231.21. The trade was a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jessica Newcomb sold 8,200 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total transaction of $198,604.00. Following the transaction, the insider directly owned 59,121 shares of the company’s stock, valued at approximately $1,431,910.62. This trade represents a 12.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 52,231 shares of company stock worth $1,254,029 in the last 90 days. Corporate insiders own 6.50% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of TNGX. Nykredit A S bought a new position in shares of Tango Therapeutics during the second quarter valued at approximately $26,000. Allworth Financial LP bought a new position in Tango Therapeutics during the 2nd quarter valued at approximately $35,000. Sterling Capital Management LLC increased its holdings in shares of Tango Therapeutics by 838.8% during the third quarter. Sterling Capital Management LLC now owns 4,647 shares of the company’s stock valued at $116,000 after acquiring an additional 4,152 shares in the last quarter. Global Retirement Partners LLC purchased a new position in Tango Therapeutics in the second quarter worth about $122,000. Finally, State of Wyoming purchased a new position in Tango Therapeutics in the 1st quarter worth approximately $128,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.
Top Tango Therapeutics Stories
These are some of the TNGX stories that stood out recently:
- Positive Sentiment: An analyst upgrade was followed by a sharp rise in Tango shares, suggesting the change in rating helped support investor sentiment. Tango Therapeutics stock price up after analyst upgrade
- Positive Sentiment: Canaccord Genuity reaffirmed its Buy rating, while HC Wainwright also maintained a Buy rating and a $67 price target despite revising its forecasts. Continued Buy ratings may help offset concerns about near-term losses. Canaccord Genuity sticks to its Buy rating HC Wainwright lowers expectations
- Negative Sentiment: Tango reported a quarterly loss of $0.39 per share, wider than the $0.35 loss analysts expected, underscoring continued operating losses.
Tango Therapeutics Company Profile
Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.
Featured Stories
- Five stocks we like better than Tango Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
